(EMAILWIRE.COM, August 10, 2024 ) According to the latest research by InsightAce Analytic, the Global CD Antigen Cancer Therapy Market is valued at US$ 26.2 Bn in 2023, and it is expected to reach US$ 41.8 Bn by 2031, with a CAGR of 6.21% during the forecast period of 2024-2031.
CD antigen cancer therapy is a specialized method of treating cancer by targeting proteins found on cancer cells surfaces, called CD antigens. The CD antigen cancer therapy market is growing rapidly worldwide due to the rising cancer incidence and the expansion of R&D efforts. Several groups worldwide are researching and coordinating their efforts to find better ways to use cancer CD antigen cancer therapy. Targeted techniques offered by CD antigen cancer medicines can potentially enhance treatment outcomes, boosting market expansion. This has led to a dramatic increase in the budgets allocated to cancer research and the development of novel treatment methods. However, the industry is expected to be hindered by regulatory hurdles regarding approving and utilizing CD antigen cancer therapy. Also, the market is expected to slow down throughout the projected period due to specific manufacturing and pharmacological challenges related to this CD antigen cancer therapy development.
Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2644
List of Prominent Players in the CD Antigen Cancer Therapy Market:
Novartis AG
Roche Holdings AG
Bristol Myers Squibb Company
Gilead Sciences Inc.
Merck & Co. Inc.
Johnson & Johnson
Amgen Inc.
AbbVie Inc.
AstraZeneca PLC
Takeda Pharmaceutical Company Limited
Seattle Genetics Inc.
Biogen Inc.
Celgene Corporation
Genmab A/S
Immunomedics Inc.
Others
Market Dynamics:
Drivers-
The rising incidence of cancer in general and targeted therapies, in particular, are propelling the CD antigen cancer therapy industry forward. Recent progress in immunotherapy and biotechnology has resulted in the creation of novel CD antigen-targeting medications. Market expansion is also driven by legislative frameworks that support industry and significant investments in research & development. Additionally, CD antigen therapies have shown promising results in clinical studies, and there is a growing need for personalized therapy, which contributes to the expansion of the market.
Challenges:
There are several obstacles in the CD antigen cancer therapy industry, including complicated manufacturing methods, expensive production and development costs, and strict regulatory regulations. Conducting clinical trials to establish the safety of CD antigen cancer therapy is costly and time-consuming. Another major obstacle is the wide range of possible side effects and patient reactions. Alternative cancer treatments and problems with intellectual property also affect market expansion. For these reasons, it is difficult for novel therapies to enter the market on a large scale.
Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2024-02
Regional Trends:
The North American CD antigen cancer therapy market is anticipated to register a major market share in revenue. It is projected to grow at a high CAGR in the near future due to the rising frequency of cancers, significant funding for research and development of targeted therapies, and a heavy focus on precision medicine and customized oncology. Besides, Europe had a substantial share in the market because of rapid urbanization, enhanced healthcare facilities, and abundant discretionary income; escalating rates of breast cancer because of unhealthy lifestyle choices, including less exercise and more alcohol use, resulted in the dramatic rise of CD antigen cancer therapy market in this region.
Recent Developments:
In March 2024, Bristol Myers Squibb received FDA approval for its chimeric antigen receptor (CAR) T cell therapy; Breyanzi, a CD19-directed CART therapy, for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least two prior lines of therapy.
In 2023, Gilead Sciences, Inc. received FDA approval for its Trodelvy, Trop-2-directed antibody and topoisomerase inhibitor drug conjugate used for the treatment of metastatic triple-negative breast cancer and metastatic urothelial cancer to treat inoperable locally advanced or metastatic breast cancer in adults.
Segmentation of CD Antigen Cancer Therapy Market-
By Type of CD Antigen Targeted-
CD19
CD20
CD30
CD33
CD38
CD70
Others
By Therapy Type-
Monoclonal Antibodies (mAbs)
Antibody-Drug Conjugates (ADCs)
Chimeric Antigen Receptor (CAR) T-cell Therapy
Bi-specific T-cell Engagers (BiTEs)
Radioimmunotherapy
Immunotoxins
By Cancer Type-
Leukaemia
Lymphoma
Multiple Myeloma
Breast Cancer
Lung Cancer
Prostate Cancer
Others
Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2644
By End-User-
Hospitals
Specialty Clinics
Cancer Treatment Centers
Research Institutes
By Region-
North America-
The US
Canada
Mexico
Europe-
Germany
The UK
France
Italy
Spain
Rest of Europe
Asia-Pacific-
China
Japan
India
South Korea
South East Asia
Rest of Asia Pacific
Latin America-
Brazil
Argentina
Rest of Latin America
Middle East & Africa-
GCC Countries
South Africa
Rest of the Middle East and Africa
Empower Your Decision-Making with 180 Pages Full Report @ https://www.insightaceanalytic.com/buy-report/2444
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
